Idarucizumab is a humanized monoclonal antibody fragment (Fab) derived from an IgG1 isotype antibody that targets and inhibits the oral anticoagulant dabigatran activity, thereby reversing its anticoagulant effect. It has been approved under the trade name Praxbind.
There are no reviews yet.
Your email address will not be published. Required fields are marked *
In which application did you use the antibody? *
Did it work in your application? *
Your review *
Save my name, email, and website in this browser for the next time I comment.
Got a question or need a quote? Message us and we’ll get back to you 48 hours or less.
Lab / Company